Skip to main content

Table 1 Clinical research of targeting GLS [127]

From: Role of glutamine and its metabolite ammonia in crosstalk of cancer-associated fibroblasts and cancer cells

Mainly targets

ClinicalTrials.gov Identifier

Phase

First posted

Drug

Combination drugs

TNBC, NSCLC, renal cell carcinoma

NCT02071862

1

2014

CB-839 (Telaglenastat)

CRC

NCT03263429

1/2

2017

CB-839

Panitumumab and irinotecan

AML

NCT03047993

1/2

2017

CB-839

Azacitidine

Hematological tumors

NCT02071888

1

2014

CB-839

Clear cell renal cell carcinoma, melanoma, NSCLC

NCT02771626

1/2

2016

CB-839

Nivolumab

NSCLC, CRC

NCT03965845

1/2

2019

CB-839

Palbociclib

Clear cell renal cell carcinoma, TNBC

NCT03875313

1/2

2019

CB-839

Talazoparib

NSCLC

NCT04265534

2

2020

CB-839

Pembrolizumab

TBNC

NCT03057600

2

2017

CB-839

Paclitaxel-carboplatin

Metastatic prostate cancer

NCT04824937

2

2021

CB-839

AML, ALL

NCT02071927

1

2018

CB-839

Azacitidine

Ovarian cancer

NCT03944902

1

2019

CB-839

Niraparib

Advanced renal cell carcinoma, metastatic renal cell carcinoma

NCT03428217

2

2018

CB-839

Cabozantinib

Malignant peripheral nerve sheath tumors

NCT03872427

2

2019

Telaglenastat hydrochloride

Leptomeningeal neoplasm, metastatic lung non-small cell carcinoma, metastatic malignant neoplasm in the brain

NCT04250545

1

2020

Telaglenastat hydrochloride

Plasma cell myeloma

NCT03798678

1

2019

Telaglenastat hydrochloride

Carfilzomib dexamethasone

Astrocytoma

NCT03528642

1

2019

Telaglenastat hydrochloride

Temozolomide

NSCLC

NCT03831932

1

2019

Telaglenastat hydrochloride

Osimertinib

  1. TNBC triple negative breast cancer, NSCLC non-small cell lung cancer, CRC colorectal carcinoma, AML acute myeloid leukemia, ALL acute lymphocytic leukemia